Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 78 results for cyclophosphamide

  1. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]

    In development [GID-TA10918] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  2. Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

    Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.

    Technology appraisal guidance
    Published
    26 March 2014
    View recommendations

    Sections for TA308

  3. Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)

    Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    28 July 2010
    View recommendations

    Sections for TA193

  4. Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

    Evidence-based recommendations on rituximab for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    22 July 2009
    View recommendations

    Sections for TA174

  5. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

    Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.

    Technology appraisal guidance
    Published
    23 April 2014
    View recommendations

    Sections for TA311

  6. Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)

    Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.

    Technology appraisal guidance
    Published
    21 September 2022
    View recommendations

    Sections for TA825

  7. Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)

    Evidence-based recommendations on fludarabine (Fludara) for B-cell chronic lymphocytic leukaemia.

    Technology appraisal guidance
    Published
    26 September 2001
    View recommendations

    Sections for TA29

  8. Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381

    In development [GID-TA11461] Expected publication date: 16 April 2025

    Technology appraisal guidance
    In development

  9. Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415

    In development [GID-TA11503] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  10. Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]

    In development [GID-TA11485] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  11. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development [GID-TA11340] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  12. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA763

  13. Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell lymphoma in adults.

    Technology appraisal guidance
    Published
    12 August 2020
    View recommendations

    Sections for TA641

  14. Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

    Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

    Evidence summary
    Published
    1 March 2016

  15. Bortezomib for previously untreated mantle cell lymphoma (TA370)

    Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA370